TAFI: a promising drug target?

• References

• 1 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-39.
• 2 Hendriks D, Scharpe S, van Sande M. et al. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
• 3 Eaton DL, Malloy BE, Tsai SP. et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-38.
• 4 Wang W, Hendricks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
• 5 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
• 6 Bajzar L, Morser J, Nesheim ME. TAFI, or procarboxypeptidase B, couples the coagulation and fibrinolyic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-08.
• 7 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
• 8 Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67: 3-12.
• 9 Rijken DC, Sakharov DV. Basic principles in thrombolysis: Regulatory role of plasminogen. Thromb Res 2001; 103S: 41-49.
• 10 Guimaraes AHC, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in internal clot lysis model. Thromb Haemost 2004; 91: 473-9.
• 11 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996; 88: 2093.
• 12 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolyic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477.
• 13 Redlitz A, Tan AK, Eaton DL. et al. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
• 14 Mutch NJ, Moore NR, Wang E. et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 01: 2000-07.
• 15 Bell WR. Therapeutic Agents - Pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002; 3S: 34-44.
• 16 Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89: 1358-62.
• 17 GUSTO III Investigators. A comparison of reteplase or acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
• 18 ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-22.
• 19 InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-13.
• 20 Tebbe U, Michels R, Adgey J. et al. Randomized double blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence trial. Comparison trial of saruplase and streptokinase (COMPASS) investigators. J Am Coll Cardiol 1998; 31: 487-93.
• 21 Herrmann HC, Moliterno DJ, Ohmann EM. et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED trial. J Am Col Cardiol 2000; 36: 1489-96.
• 22 GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with firbrinolytic therapy or combination reduced fibrinolytic herapy and platelet glycoprotein Iib/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
• 23 Fujise K, Revelle BM, Stacy L. et al. A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. Circulation 1997; 95: 715-22.
• 24 Runge MS, Harker LA, Bode C. et al. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 1996; 94: 1412-22.
• 25 Minnema MC, Friedrich PW, von Levi M. et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
• 26 Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
• 27 Nagashima M, Werner M, Wang M. et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
• 28 Refino CJ, Schmitt D, Pater C. et al. Carboxypeptidase inhibitor markedly improves the potency of tPA in vivo. Fibrinolysis Proteolysis 1998; 12: 29.
• 29 Mattson C, Bjorkmann JA, Abrahamsson T. et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87: 557-62.
• 30 Nagashima M, Yin ZF, Zhaou L. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
• 31 Swaisgood CM, Schmitt D, Eaton D. et al. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
• 32 Mosnier LO, von dem Borne PAK, Meijers JCM. et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of intrinsic coagulation. Thromb Haemost 1998; 80: 829-35.
• 33 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fbrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000; 95: 2855-59.
• 34 Yano Y, Kitagawa N, Gabazza EC. et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736-41.
• 35 Aubert H, Frere C, Aillaud MF. et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 01: 791-97.
• 36 Montaner J, Ribo M, Monasterio J. et al. Thrombin-activatable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34: 1038-40.
• 37 Morange PE, Juhan-Vague I, Scarabin PY. et al. Association between TAFI antigen and Ala14Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb Haemost 2003; 89: 554-60.
• 38 Silveira A, Schatterman K, Goossens F. et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
• 39 Juhan-Vague I, Morange PE, Aubert H. et al. Plasma thrombin activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
• 40 Brouwers GJ, Leebeek FW, Tanck MW. et al. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003; 90: 92-100.
• 41 Te Velde EA, Wagenhaar GTM, Reijerkerk A. et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 01: 2087-96.
• 42 Myles T, Nishimura T, Yun T. et al. Thrombin activatable fibrinolysis inhibitor: A potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
• 43 Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 01: 1343-48.